Wall Street brokerages expect Chromadex Corp (NASDAQ:CDXC) to announce ($0.13) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for Chromadex’s earnings. Chromadex posted earnings per share of ($0.15) during the same quarter last year, which indicates a positive year-over-year growth rate of 13.3%. The company is expected to report its next quarterly earnings results on Thursday, August 8th.
According to Zacks, analysts expect that Chromadex will report full year earnings of ($0.46) per share for the current financial year, with EPS estimates ranging from ($0.47) to ($0.45). For the next financial year, analysts expect that the business will report earnings of ($0.05) per share, with EPS estimates ranging from ($0.14) to $0.09. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Chromadex.
Chromadex (NASDAQ:CDXC) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.04). The firm had revenue of $10.05 million during the quarter, compared to analyst estimates of $9.80 million. Chromadex had a negative return on equity of 108.84% and a negative net margin of 94.78%.
A number of analysts recently commented on the company. BidaskClub lowered Zebra Technologies from a “hold” rating to a “sell” rating in a research report on Friday, May 24th. Zacks Investment Research lowered Haynes International from a “hold” rating to a “sell” rating in a research report on Wednesday, May 8th. ValuEngine lowered Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, March 25th. Finally, HC Wainwright set a $55.00 price objective on Acer Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, May 28th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $6.00.
Several institutional investors have recently bought and sold shares of the company. Resources Investment Advisors Inc. grew its position in shares of Chromadex by 125.0% during the 4th quarter. Resources Investment Advisors Inc. now owns 9,000 shares of the company’s stock worth $31,000 after buying an additional 5,000 shares during the period. Northern Trust Corp grew its position in shares of Chromadex by 1.2% during the 4th quarter. Northern Trust Corp now owns 411,436 shares of the company’s stock worth $1,412,000 after buying an additional 5,009 shares during the period. BNP Paribas Arbitrage SA acquired a new position in shares of Chromadex during the 1st quarter worth about $34,000. Woodard & Co. Asset Management Group Inc. ADV bought a new position in shares of Chromadex during the 1st quarter valued at about $42,000. Finally, Rhumbline Advisers lifted its holdings in shares of Chromadex by 53.3% during the 4th quarter. Rhumbline Advisers now owns 48,511 shares of the company’s stock valued at $166,000 after purchasing an additional 16,863 shares in the last quarter. Institutional investors own 18.11% of the company’s stock.
CDXC stock traded up $0.27 during midday trading on Thursday, reaching $4.77. The stock had a trading volume of 15,775 shares, compared to its average volume of 315,925. The business’s fifty day moving average price is $4.19. The company has a current ratio of 2.24, a quick ratio of 1.68 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $241.52 million, a price-to-earnings ratio of -7.68 and a beta of 1.26. Chromadex has a twelve month low of $2.79 and a twelve month high of $5.00.
Chromadex Company Profile
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.
Featured Story: Trading Strategy
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.